1. Human Organ Chip Models Recapitulate Orthotopic Lung Cancer Growth, Therapeutic Responses, and Tumor Dormancy In Vitro
   Bryan A. Hassell et al, 2017, Cell Reports CrossRef
2. Selective disruption of an oncogenic mutant allele by CRISPR/Cas9 induces efficient tumor regression
   Taeyoung Koo et al, 2017 CrossRef
3. Gel-based cell manipulation method for isolation and genotyping of single-adherent cells
   Ryo Negishi et al, 2018, Analyst CrossRef
4. Coins in microfluidics: From mere scale objects to font of inspiration for microchannel circuits
   Gabriele Pitingolo et al, 2019, Biomicrofluidics CrossRef
5. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer
   G Sette et al, 2015, Cell Death Dis CrossRef
6. Antitumor Activity of DFX117 by Dual Inhibition of c-Met and PI3Kα in Non-Small Cell Lung Cancer
   Yanhua Fan et al, 2019, Cancers CrossRef
7. An effective drug sensitizing agent increases gefitinib treatment by down regulating PI3K/Akt/mTOR pathway and up regulating autophagy in non-small cell lung cancer.
   Jue Zhang et al, 2019, Biomed Pharmacother CrossRef
8. Yiqi Chutan Tang Reduces Gefitinib-Induced Drug Resistance in Non-Small-Cell Lung Cancer by Targeting Apoptosis and Autophagy.
   Jue Zhang et al, 2020, Cytometry A CrossRef
9. Rapid detection and genotyping of ALK fusion variants by adapter multiplex PCR and high-resolution melting analysis
   Mei Li et al, 2019, Lab Invest CrossRef
10. Phosphorylation of a Human Microprotein Promotes Dissociation of Biomolecular Condensates
    Zhenkun Na et al, 2021, J. Am. Chem. Soc. CrossRef
11. Regulation of EGFR signalling by palmitoylation and its role in tumorigenesis
    Yasmin A. Kadry et al, 2021, Open Biol. CrossRef
12. Emerging Nanotherapeutic Approaches to Overcome Drug Resistance in Cancers with Update on Clinical Trials.
    Syed Nasir Abbas Bukhari, 2022, Pharmaceutics CrossRef
13. Drug resistance in cancer: mechanisms and tackling strategies.
    Tanweer Haider et al, 2020, Pharmacol Rep CrossRef
14. MnTnHex-2-PyP5+ Displays Anticancer Properties and Enhances Cisplatin Effects in Non-Small Cell Lung Cancer Cells
    Rita B. Soares et al, 2022, Antioxidants CrossRef
15. Phase 1 study of DS‐1205c combined with gefitinib for EGFR mutation‐positive non‐small cell lung cancer
    Koichi Goto et al, 2023, Cancer Medicine CrossRef
16. Macrophage renewal modes affect acquired resistance to gefitinib in EGFR‑mutant lung cancer PC‑9 cells
    Baoxia Zhao et al, 2022, Oncol Rep CrossRef
17. Nanoparticle-mediated cancer cell therapy: basic science to clinical applications
    Jaya Verma et al, 2023, Cancer Metastasis Rev CrossRef
18. Cytosolic malic enzyme and glucose‐6‐phosphate dehydrogenase modulate redox balance in NSCLC with acquired drug resistance
    Maoxin Ran et al, 2023, The FEBS Journal CrossRef
19. The Redox-Active Manganese(III) Porphyrin, MnTnBuOE-2-PyP5+, Impairs the Migration and Invasion of Non-Small Cell Lung Cancer Cells, Either Alone or Combined with Cisplatin
    Rita B. Soares et al, 2023, Cancers CrossRef
20. A single cell RNAseq benchmark experiment embedding “controlled” cancer heterogeneity
    Maddalena Arigoni et al, 2024, Sci Data CrossRef
21. The Diagnostic Value of ACSL1, ACSL4, and ACSL5 and the Clinical Potential of an ACSL Inhibitor in Non-Small-Cell Lung Cancer
    Yunxia Ma et al, 2024, Cancers CrossRef
22. Unveiling the altered metabolic pathways induced by nivolumab in non-small cell lung cancer via GC–MS metabolomics approach coupled with multivariate analysis
    Manal E. Alosaimi et al, 2024, Journal of Chromatography B CrossRef
23. IGFBP2/ITGA5 promotes gefitinib resistance via activating STAT3/CXCL1 axis in non-small cell lung cancer
    Hengxiao Lu et al, 2024, Cell Death Dis CrossRef
24. Digital Profiling of Tumor Extracellular Vesicle-Associated RNAs Directly from Unprocessed Blood Plasma
    Elizabeth Maria Clarissa et al, 2025, ACS Nano CrossRef